Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYou've just finished your second week on Wegovy and realise you've barely thought about food. Not slightly less hungry — not hungry at all. That's a recognised response to semaglutide's action on appetite-regulating signals in the brain and gut, and for most people it settles as the body adjusts. The important thing is that even when appetite disappears almost entirely, your body still needs protein, fluids and enough energy to avoid muscle loss, so ignoring the signal altogether isn't the right move. Wegovy is a prescription-only medicine, and questions about your specific dose and eating pattern are best worked through with your prescribing clinician.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture this: you sit down at a meal you'd normally enjoy, take two bites, and feel completely done. No nausea, no discomfort, just nothing. Wegovy (semaglutide) works as a GLP-1 receptor agonist, mimicking a gut hormone that tells the brain satiety has arrived. It also slows how quickly food leaves the stomach, so signals of fullness linger longer than usual. The result, for some people, is appetite suppression that goes further than expected, not just reduced hunger but something close to its absence.
This effect tends to be sharpest at the start of treatment or in the days following a dose step-up, when semaglutide's concentration in the body is rising toward a new steady state. The NHS semaglutide patient page notes that reduced appetite is an expected part of how the medicine works. For most people the intensity moderates after a week or two, settling into a milder, more manageable reduction. A smaller number find appetite stays very low throughout treatment, which is worth flagging to their prescriber.
Feeling this way doesn't mean something has gone wrong. It means the medicine is doing what it's designed to do, just, perhaps, more emphatically than you anticipated. What matters is what you do with it. If you're wondering whether this experience is as common as it feels, our overview of how Wegovy affects hunger covers the mechanism in more detail.
When you're not hungry at all on Wegovy, the temptation is to eat very little or skip meals entirely. It feels logical, the body seems content, so why push it? The problem is that significant calorie restriction, especially without enough protein, accelerates the loss of lean muscle mass alongside fat. Clinical trials consistently show that weight loss from GLP-1 medicines includes some muscle loss, and the way to minimise that is deliberate protein intake, not waiting for hunger to return.
Adults typically need somewhere in the region of 1.2–1.6 grams of protein per kilogram of body weight during active weight loss, a range your prescriber or a dietitian can refine for you. The practical challenge on treatment is fitting that in when appetite is low. Small, protein-led meals work better than forcing large portions: a couple of eggs, some Greek yogurt, a small portion of fish or chicken. Staying hydrated matters too, because dehydration can be mistaken for nausea and make things feel worse.
There's also a case for not letting meals disappear entirely from your day, even when you're not hungry. Skipping all structure tends to mean the protein gap widens without you noticing. For practical ideas on what to eat when appetite has all but gone, the Wegovy eating guide for low-appetite days is worth reading alongside this page.
There's a difference between appetite being genuinely suppressed (uncomfortable but manageable) and being unable to eat or drink adequately over several days. The latter matters clinically. Prolonged very low intake can lead to dehydration, electrolyte imbalance, and further muscle loss, none of which supports the goals of treatment.
Signs worth contacting your prescriber about include: struggling to keep fluids down, feeling faint or very weak, losing weight faster than around 1–2kg per week over a sustained period, or simply finding it impossible to eat anything at all for more than two or three days. Your clinical team can discuss whether slowing the dose schedule makes sense, or whether additional support is needed.
The MHRA's January 2026 Drug Safety Update on GLP-1 medicines also highlighted that severe, persistent stomach pain (especially if it spreads toward the back) should prompt urgent medical attention, as this can signal pancreatitis. Report any unexpected side effects using the MHRA Yellow Card scheme.
If your appetite swings in the other direction at times and you find yourself unexpectedly hungry, that's also worth understanding, the page on feeling hungry on Wegovy covers why that can happen even on treatment.
Most people who find themselves completely without appetite in the early weeks of Wegovy do see it ease. The body adapts. Meal sizes that felt impossible at week two become routine by week six. That said, adaptation doesn't mean ignoring the experience in the meantime.
A question our prescribers hear regularly is whether it's safe to eat very little as long as weight is coming off. The honest answer is that weight loss at any cost isn't the aim, preserving muscle, sustaining energy, and building habits that last beyond treatment are. For a broader view of eating well while on semaglutide, the general Wegovy eating guide offers practical grounding.
If you're considering starting Wegovy and want to understand the full clinical picture before committing, our Wegovy treatment page covers eligibility and how the process works. And if cost is part of the question, the Wegovy cost guide sets out what private treatment typically involves in the UK. When you're ready to take the next step, check your eligibility with our prescribers, there's no obligation, and the consultation is free.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.